Description
Sino Biological has established an integrated, high-throughput technology platform specifically designed to accelerate AI-driven lead discovery and optimization. Our platform combines automated, high-throughput antibody production systems—including mammalian cell expression and cell-free protein synthesis—with comprehensive developability assessment tools. This enables the rapid synthesis of thousands of AI-derived antibody variants, generating large volumes of high-quality datasets essential for training and enhancing AI models. By seamlessly translating AI-designed sequences into viable therapeutic candidates, the platform bridges the gap between computational design and experimental validation.